Patrick Vanderheyden

Distinction between surmountable and insurmountable selective AT₁ receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT₁ receptors

Patrick Vanderheyden, Frederik Fierens, J.-P. De Backer et al. · British Journal of Pharmacology · 1999 · 145 citations · Full text

Medicine, Pharmacology, Cell Signaling +14

Angiotensin IV Activates the Nuclear Transcription Factor-κB and Related Proinflammatory Genes in Vascular Smooth Muscle Cells

Vanesa Esteban, Mónica Rupérez, Elsa Sánchez‐López et al. · Circulation Research · 2005 · 97 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding

Frederik Fierens, Patrick Vanderheyden, Jean‐Paul De Backer et al. · European Journal of Pharmacology · 1999 · 88 citations

Medicine, Cardiology, Pharmacology +14

Monoclonal antibodies against the native or denatured forms of muscarinic acetylcholine receptors.

Camille André, J G Guillet, J.-P. De Backer et al. · The EMBO Journal · 1984 · 87 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Binding of the antagonist []candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells

Frederik Fierens, Patrick Vanderheyden, Jean-Paul De Backer et al. · European Journal of Pharmacology · 1999 · 87 citations

Medicine, Pharmacology, Cell Signaling +3